Movatterモバイル変換

[0]ホーム
URL:

CN113248501B - CLY series compounds, preparation method thereof and application thereof in preparing medicines - Google Patents

CLY series compounds, preparation method thereof and application thereof in preparing medicinesDownload PDF

Info

Publication number
CN113248501B
CN113248501BCN202110668896.0ACN202110668896ACN113248501BCN 113248501 BCN113248501 BCN 113248501BCN 202110668896 ACN202110668896 ACN 202110668896ACN 113248501 BCN113248501 BCN 113248501B
Authority
CN
China
Prior art keywords
cly
compound
pharmaceutically acceptable
formula
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110668896.0A
Other languages
Chinese (zh)
Other versions
CN113248501A (en
Inventor
陈敏
吴永平
戴蓓英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Weiyouzhong Pharmaceutical Co ltd
Original Assignee
Nanjing Weiyouzhong Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202110668896.0ApriorityCriticalpatent/CN113248501B/en
Application filed by Nanjing Weiyouzhong Pharmaceutical Co ltdfiledCriticalNanjing Weiyouzhong Pharmaceutical Co ltd
Publication of CN113248501ApublicationCriticalpatent/CN113248501A/en
Application grantedgrantedCritical
Publication of CN113248501BpublicationCriticalpatent/CN113248501B/en
Priority to EP22824326.7Aprioritypatent/EP4357345A4/en
Priority to JP2024510304Aprioritypatent/JP2024532854A/en
Priority to PCT/CN2022/099496prioritypatent/WO2022262854A1/en
Priority to KR1020247001632Aprioritypatent/KR20240022602A/en
Priority to US18/571,578prioritypatent/US20240300945A1/en
Priority to CN202310688735.7Aprioritypatent/CN116803391A/en
Activelegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Images

Classifications

Landscapes

Abstract

The invention discloses a CLY series compound and a preparation method and application thereof in preparing a medicament, wherein the CLY series compound is a compound with a structure shown in a formula I, a tautomer, a solvate or a pharmaceutically acceptable salt thereof, and animal model experiments show that the CLY series compound can obviously reduce the level of tyrosinase in the skin and blood of a chloasma mouse model, reduce the expression of hepatocyte factor (SCF) and C-kit protein in the skin and inhibit the formation of chloasma pigment; the healing of the skin wound surface can be obviously promoted, and the scar formation is reduced; the hair growth of a baldness mouse model can be obviously promoted, and the damage to hair follicles is reduced; the compound CLY series can obviously relieve rabbit ear acne model symptoms, and reduce pore blockage and acne formation. The compound can be used alone or in combination with other medicines, and provides a new medicine choice for treating the diseases.
Figure 100004_DEST_PATH_IMAGE001
Formula I.

Description

CLY series compounds, preparation method thereof and application thereof in preparing medicines
Technical Field
The invention belongs to the field of medicinal chemistry, and particularly relates to a CLY series compound, a preparation method thereof and application thereof in preparing medicines.
Background
Chloasma is an acquired pigmentary disturbance disease which is well developed in middle-aged and young women, the pathogenesis of the chloasma is extremely complex, the influence factors are numerous, and the deposition of skin melanin caused by various reasons is the direct reason for causing the chloasma. The tyrosinase generates melanin after a series of oxidation reactions. Tyrosine is oxidized into dopa in melanosomes under the action of tyrosinase, dopa is further oxidized into dopaquinone by dopa oxidase, and dopaquinone is finally oxidized into melanin under the action of tyrosinase. The series of oxidation and oxidation resistance reaction disorder appearing in the process can cause and promote the occurrence and development of chloasma, and the increase of tyrosine is the main material basis of the chloasma. When the series of oxidation reactions are disturbed in balance, excessive oxygen radicals are generated in vivo, simultaneously, the activities of antioxidase such as superoxide dismutase (SOD) and the like are reduced, membrane lipid is overoxidized to form lipid peroxide, the lipid peroxide is unstable and can be rapidly decomposed to generate aldehydes, the final product Malondialdehyde (MDA) is correspondingly increased and can rapidly attack phospholipid and protein, so that oxidative damage of pigment cells is caused, the oxidation reaction of tyrosinase is promoted, and melanin is increased and deposited on the basal layer of skin. Chloasma easily appears repeatedly and is difficult to treat. The product which can really solve chloasma in the market is few, and the color spot is easy to recur. Hydroquinone is the most widely used whitening agent at the earliest time, but has been limited in the treatment of whitening and chloasma due to uneven distribution of skin pigments, strong irritation, even possible carcinogenesis and the like.
Scars are the symptoms that damages caused by physical, biological, chemical and other factors act on the skin soft tissues of a human body, the skin soft tissues are seriously damaged and cannot be completely and normally repaired, and the appearance and the function are influenced after the fibrous tissues are replaced and repaired. The scars bring great physical and mental pains to patients, especially scars left after burns, scalds and severe trauma. The treatment difficulty of scars is high, and at present, only reddish and hard scars can be softened and lightened, wide scars are narrowed, thick scars are thinned, and the scars cannot be completely and thoroughly eliminated. The current commonly used methods for treating scars are: surgical treatment, laser treatment, cryotherapy, drug therapy, and the like. The commonly used drugs are mainly: glucocorticoids and tretinoin. The glucocorticoid has the functions of resisting inflammation, virus, shock and the like, and has obvious effect of resisting tissue fibrosis, but the glucocorticoid has many toxic and side effects after long-term use. The tretinoin is an intermediate product of vitamin A metabolism in vivo, is a vitamin A related medicament, and can relieve local inflammation, promote epithelial cell growth, reduce collagen synthesis, reduce DNA synthesis of fibroblast, and inhibit cell growth. The higher the concentration of the retinoid, the more obvious the growth inhibition effect is. However, the retinoic acid has limited curative effect, has few toxic and side effects in system application, has obvious skin irritation when externally applied and increases along with the increase of concentration.
Alopecia Areata (AA) is a non-scarring alopecia with a generally normal topical skin. Usually, the hair is a sudden alopecia and the whole scalp is seriously affected, which is called Alopecia Totalis (AT), and when all hairs including axillary hair and pubic hair are affected, it is called Alopecia Universalis (AU), which has serious influence on the appearance and mind of the patient. The glucocorticoid commonly used for severe alopecia areata mainly comprises prednisolone, compound betamethasone and the like, and can be orally taken, externally used or injected in the skin. For patients who do not use glucocorticoid medicaments, immunosuppressant treatment can be adopted, and common medicaments comprise cyclosporine, methotrexate, glucocorticoid and immunosuppressant, but the medicaments have many side effects.
Androgenetic alopecia (AGA) is an androgen-dependent, hereditary hair loss, a common and frequently encountered disease. The disease is usually about 20-30 years old. Alopecia is mainly at the top of the head, usually beginning from the hairline on both sides of the forehead, and also beginning from the top. The bald area gradually expands upwards, the hair gradually becomes thin and slender, most or all of the hair at the top of the head falls off, but the hair at the back of the pillow and above the temples on both sides is dependent and takes on a horseshoe-shaped appearance, and the hair in the band-shaped area keeps normal. The hair loss site has a bright skin, and the pores are reduced or a few vellus hairs remain. The rate, extent and severity of hair loss is influenced by genetics and individuals. Generally, the disease develops fastest in about 30 years old, and severe alopecia totalis is rare. Women mostly have diffuse alopecia on the top of the head, and the hair on the top of the head becomes thin. Epidemiological investigation in China shows that the prevalence rate of androgenetic alopecia in men is 21.3%, and that in women is 6.0%. The etiology and pathogenesis of androgenetic alopecia are not clear, and it is believed that androgen and its receptor play a key role in the pathogenesis of the disease, and type ii 5 a-reductase is an important factor in the pathogenesis of the disease. Under normal physiological state, the androgen can stimulate and promote the growth and development of hair in vivo, but can induce hair loss at certain specific parts; testosterone, the major androgen in the body, is converted to dihydrotestosterone by 5 a-reductase, which causes the transition from terminal hair to vellus hair, ultimately resulting in hair loss. At present, no ideal treatment method exists.
Acne (commonly known as acne) is a chronic inflammatory disease well-developed in the pilosebaceous glands, with a morbidity rate of about 9.4%. The generation of acne is closely related to the physiological and pathological changes of adolescent skin. The clinical manifestations mainly include acne, papule, pustule, nodule, cyst, scar, etc., which bring serious influence to the appearance and mind of the patient. Acne is associated with a plurality of pathogenesis, the follicular keratosis abnormality forms comedo which is an important basis for the pathogenesis of the disease, and inflammation and infection are the pathogenesis factors of the acne. The sebaceous glands of acne patients are large, the secretion of the sebaceous glands is increased, the linoleic acid level in sebum is relatively reduced, the synthesis of fat is influenced, and follicular epithelium lacks fatty acid, so that follicular hyperkeratosis is induced, epithelial cells cannot normally fall off, the mouth of the pilosebaceous glands is excessively small, sebum cannot be smoothly discharged, and acne is formed. The follicular sebaceous gland orifice is blocked to form an anoxic environment in the follicular sebaceous gland, so that anaerobic propionibacterium acnes is massively propagated, sebum is decomposed, chemical chemotactic factors are generated, and white blood cells are gathered to form pimples. A large amount of neutrophils in the pilosebaceous gland are gathered, and inflammatory reaction occurs after the propionibacterium acnes is swallowed, so that a large amount of pus cells are accumulated to form pustules and cysts, and sunken scars are easily formed after healing. At present, the medicines for clinically eliminating the keratotic plug and the acne are mainly retinoid medicines. The retinoid drug can inhibit keratinization, reduce sebum secretion, promote normal keratinization of keratinocyte, and has immunity regulating and antiinflammatory effects, thereby reducing formation of acne, pimple and pustule. However, the external application of the retinoid medicine can stimulate the skin, easily cause red swelling and stabbing pain, aggravate the original skin damage, and the long-term external application of the retinoid medicine can cause skin thinning, light sensitivity, skin barrier damage and the like, while the oral administration of the retinoid medicine has adverse effects of liver damage, blood fat increase and the like.
Psoriasis is a common chronic recurrent inflammatory skin disease, and the prevalence rate of psoriasis patients in natural people is 0.1-3% worldwide. It is characterized by red or brown maculopapule or plaque, covered with silvery-white scale on the surface, with clear boundary, mostly occurring on the scalp and limbs, with pustular lesion or arthritis symptoms in some patients, or reddening and desquamation of the whole skin to show erythroderma. The course of psoriasis often recurs persistently or frequently. Moderate to severe patients are associated with increased risk of metabolic syndrome and cardiovascular damage. The current treatment situation is as follows: glucocorticoid cream or ointment has good effect, but is not suitable for long-term, continuous and large-area use; the tretinoin cream has good effect of treating plaque psoriasis, but has skin irritation and influences long-term use; vitamin D3 derivatives such as calcipotriol are not suitable for use on the face and skin folds; calcineurin inhibitors (such as tacrolimus, pimecrolimus cream or ointment, and the like) can be applied to scalp, skin folds, genitals and other parts, but long-term and large-area application can increase the occurrence risk of lymph cancer and skin cancer; various keratolytic agents (such as tar preparations, anthralin ointment, 10-15% camptothecin ointment, salicylic acid ointment, etc.) can also be used externally, but the effect is limited. Immunosuppressive drugs are mainly used for erythrodermic psoriasis, pustule psoriasis and arthropathy psoriasis, but have many adverse reactions after long-term use, and commonly have bone marrow suppression, liver and kidney function damage, increased infection risk and the like.
Eczema (also known as atopic dermatitis and atopic dermatitis) is an inflammatory reaction of the skin with intense itching caused by various internal and external factors. It is divided into three stages of acute stage, subacute stage and chronic stage. The acute stage is prone to exudation, while the chronic stage is infiltrative and hypertrophic. Some patients directly manifest chronic eczema. The skin lesion has the characteristics of polymorphism, symmetry, pruritus, easy repeated attack and the like. Eczema has complex etiology, is easy to repeatedly attack after treatment is improved, and is difficult to radically cure.
For the above diseases, the current treatment methods are far from meeting clinical requirements, and more new medicines with good curative effect, less side effects and low price are needed to be searched for to control the disease progression and reduce the occurrence of relapse and complications.
Disclosure of Invention
The invention aims to provide a CLY series compound or a pharmaceutically acceptable salt thereof with medicinal value.
Another object of the present invention is to provide a process for producing the above compound.
It is a further object of the present invention to provide the use of the above compounds.
The object of the invention can be achieved by the following measures:
the invention provides compounds having the structure of formula I, tautomers thereof, solvates thereof, or pharmaceutically acceptable salts thereof,
Figure 212278DEST_PATH_IMAGE001
formula I
Wherein:
R1is a substituted or unsubstituted pyridyl, isoquinolinyl or pyrrolopyridyl; the substituent is H, chlorine or (C)1-C4) An alkyl group;
R2is H, halogen, hydroxy, methoxy, amino or methyl;
when R is3Is composed of
Figure 988604DEST_PATH_IMAGE002
、
Figure 144779DEST_PATH_IMAGE003
、
Figure 863205DEST_PATH_IMAGE004
Or
Figure 3200DEST_PATH_IMAGE005
， R4Is composed of
Figure 583217DEST_PATH_IMAGE006
、
Figure 125056DEST_PATH_IMAGE007
、
Figure 483225DEST_PATH_IMAGE008
、
Figure 844937DEST_PATH_IMAGE009
、
Figure 822120DEST_PATH_IMAGE010
、
Figure 952887DEST_PATH_IMAGE011
、
Figure 498269DEST_PATH_IMAGE012
、
Figure 347276DEST_PATH_IMAGE013
、
Figure 862571DEST_PATH_IMAGE014
、
Figure 506567DEST_PATH_IMAGE015
、
Figure 81905DEST_PATH_IMAGE016
、
Figure 418208DEST_PATH_IMAGE017
、
Figure 878139DEST_PATH_IMAGE018
Or
Figure 249078DEST_PATH_IMAGE019
；
When R is3Is composed of
Figure 385530DEST_PATH_IMAGE020
、
Figure 209129DEST_PATH_IMAGE021
、
Figure 472752DEST_PATH_IMAGE022
、
Figure 432617DEST_PATH_IMAGE023
、
Figure 349758DEST_PATH_IMAGE024
Or
Figure 50866DEST_PATH_IMAGE025
， R4Is composed of
Figure 711655DEST_PATH_IMAGE026
、
Figure 526027DEST_PATH_IMAGE027
、
Figure 755014DEST_PATH_IMAGE028
、
Figure 553206DEST_PATH_IMAGE029
、
Figure 17685DEST_PATH_IMAGE030
、
Figure 811198DEST_PATH_IMAGE031
、
Figure 335720DEST_PATH_IMAGE032
、
Figure 355629DEST_PATH_IMAGE033
、
Figure 358220DEST_PATH_IMAGE034
、
Figure 288130DEST_PATH_IMAGE035
、
Figure 983553DEST_PATH_IMAGE036
、
Figure 225179DEST_PATH_IMAGE037
Or
Figure 159024DEST_PATH_IMAGE038
；
When R is3Is composed of
Figure 68074DEST_PATH_IMAGE039
，R4Is composed of
Figure 934399DEST_PATH_IMAGE040
、
Figure 804266DEST_PATH_IMAGE041
、
Figure 148660DEST_PATH_IMAGE042
、
Figure 912217DEST_PATH_IMAGE043
、
Figure 74077DEST_PATH_IMAGE044
、
Figure 555873DEST_PATH_IMAGE045
、
Figure 703958DEST_PATH_IMAGE046
、
Figure 462967DEST_PATH_IMAGE047
、
Figure 671094DEST_PATH_IMAGE048
Or
Figure 374608DEST_PATH_IMAGE049
；
Wherein:
R6and R8Each independently is H, methyl, halogen or (C)1-C4) Alkyl, and R6And R8Not both are halogen; preferably, R6Is H or methyl, and R8Is H;
R7is hydroxy, (C)1-C4) Alkoxy group, (C)1-C4) Alkoxycarbonyl oxy (C)1-C4) Alkyl or (C)1-C4) Alkylcarbonyloxy (C)1-C4) An alkyl group;
R10and R11Each independently is H, (C)1-C4) Alkyl or (C)3-C6) A cycloalkyl group;
R12selected from H, halogen, -OH, -NH2Or (C)1-C3) An alkyl group;
R13is H, (C)1-C4) Alkyl, (C)1-C4) Alkylcarbonyloxy (C)1-C4) Alkyl or (C)1-C4) Alkoxycarbonyl oxy (C)1-C4) Alkyl groups;
R14is H, (C)1-C4) Alkyl, (C)1-C4) Alkylcarbonyloxy (C)1-C4) Alkyl or (C)1-C4) Alkoxycarbonyl oxy (C)1-C4) An alkyl group;
R15is hydroxy, tetrazolyl, (C)1-C2) Alkylsulfonyl or trifluoromethylsulfonyl, and R16Is H, (C)1-C4) Alkyl, (C)1-C4) Alkylcarbonyloxy (C)1-C4) Alkyl or (C)1-C4) Alkoxycarbonyl oxy (C)1-C4) An alkyl group.
In some embodiments, R1Is isoquinolin-1-ylAnd R is1Optionally mono-substituted with chlorine or methyl.
In some embodiments, R2Is H, hydroxy or methyl.
In some embodiments, R1Is a substituted or unsubstituted pyridyl or pyrrolopyridyl; the substituent is H, chlorine or methyl.
In some embodiments, R12Selected from H, halogen, -OH, -NH2Or a methyl group; in some embodiments, R12Is selected from H.
The present invention provides compounds having the structure of formula I-a, tautomers thereof, solvates thereof, or pharmaceutically acceptable salts thereof,
Figure 60804DEST_PATH_IMAGE050
formula I-a
Wherein,
when R is3Selected from the following substituted or unsubstituted groups:
Figure 923587DEST_PATH_IMAGE051
or
Figure 302616DEST_PATH_IMAGE052
，R4Is composed of
Figure 493425DEST_PATH_IMAGE006
、
Figure 858679DEST_PATH_IMAGE007
、
Figure 451334DEST_PATH_IMAGE008
、
Figure 266843DEST_PATH_IMAGE009
、
Figure 69583DEST_PATH_IMAGE010
、
Figure 97582DEST_PATH_IMAGE011
、
Figure 544744DEST_PATH_IMAGE012
、
Figure 265575DEST_PATH_IMAGE013
、
Figure 306344DEST_PATH_IMAGE014
、
Figure 138033DEST_PATH_IMAGE015
、
Figure 439702DEST_PATH_IMAGE016
、
Figure 724577DEST_PATH_IMAGE017
、
Figure 377275DEST_PATH_IMAGE018
Or
Figure 747077DEST_PATH_IMAGE019
；
When R is3Is composed of
Figure 309776DEST_PATH_IMAGE053
、
Figure 372410DEST_PATH_IMAGE054
、
Figure 246825DEST_PATH_IMAGE055
、
Figure 685897DEST_PATH_IMAGE056
、
Figure 86791DEST_PATH_IMAGE057
Or
Figure 320326DEST_PATH_IMAGE058
，R4Is composed of
Figure 682038DEST_PATH_IMAGE026
、
Figure 534587DEST_PATH_IMAGE027
、
Figure 930933DEST_PATH_IMAGE028
、
Figure 335370DEST_PATH_IMAGE029
、
Figure 184377DEST_PATH_IMAGE030
、
Figure 824306DEST_PATH_IMAGE031
、
Figure 75159DEST_PATH_IMAGE032
、
Figure 650497DEST_PATH_IMAGE033
、
Figure 127745DEST_PATH_IMAGE034
、
Figure 446731DEST_PATH_IMAGE035
、
Figure 552091DEST_PATH_IMAGE036
、
Figure 298330DEST_PATH_IMAGE037
Or
Figure 980984DEST_PATH_IMAGE038
；
When R is3Is composed of
Figure 103661DEST_PATH_IMAGE059
，R4Is composed of
Figure 329106DEST_PATH_IMAGE040
、
Figure 121612DEST_PATH_IMAGE041
、
Figure 432508DEST_PATH_IMAGE042
、
Figure 93296DEST_PATH_IMAGE043
、
Figure 907669DEST_PATH_IMAGE044
、
Figure 377134DEST_PATH_IMAGE045
、
Figure 175326DEST_PATH_IMAGE046
、
Figure 374226DEST_PATH_IMAGE047
、
Figure 184050DEST_PATH_IMAGE048
Or
Figure 708573DEST_PATH_IMAGE049
；
Wherein: r6And R8Each independently is H, methyl, halogen or (C)1-C4) Alkyl, and R6And R8Not both are halogen; preferably, R6Is H or methyl, and R8Is H;
R7is hydroxy, (C)1-C4) Alkoxy group, (C)1-C4) Alkoxycarbonyl oxy (C)1-C4) Alkoxy or (C)1-C4) Alkylcarbonyloxy (C)1-C4) An alkoxy group;
Rl0and R11Each independently is H, (C)1-C4) Alkyl or (C)3-C6) A cycloalkyl group;
R12selected from H, halogen, -OH, -NH2Or (C)1-C3) An alkyl group;
R13is H, (C)1-C4) Alkyl, (C)1-C4) Alkylcarbonyloxy (C)1-C4) Alkyl or (C)1-C4) Alkoxycarbonyl oxy (C)1-C4) An alkyl group;
R14is H, (C)1-C4) Alkyl, (C)1-C4) Alkylcarbonyloxy (C)1-C4) Alkyl or (C)1-C4) Alkoxycarbonyl oxy (C)1-C4) An alkyl group;
R15is hydroxy, tetrazolyl, (C)1-C2) Alkylsulfonyl or trifluoromethylsulfonyl, and R16Is H, (C)1-C4) Alkyl, (C)1-C4) Alkylcarbonyloxy (C)1-C4) Alkyl or (C)1-C4) Alkoxycarbonyl oxy (C)1-C4) An alkyl group.
In some embodiments, a compound having the structure of formula I-a, a tautomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, R6Is H, and R8Is H.
In some embodiments, a compound having the structure of formula I-a, a tautomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, R12Selected from H, halogen, -OH, -NH2Or a methyl group; in some embodiments, R12Is selected from H.
In some embodiments, a compound having the structure of formula I-a, a tautomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, R11Is H, and R10Is H or methyl, R13Is composed of
Figure 462902DEST_PATH_IMAGE060
Or
Figure 731072DEST_PATH_IMAGE061
。
The present invention provides compounds having the structure of formula I-b, tautomers thereof, solvates thereof, or pharmaceutically acceptable salts thereof,
Figure 910250DEST_PATH_IMAGE062
formula I-b
Wherein,
R3comprises the following steps:
Figure 340094DEST_PATH_IMAGE063
or
Figure 847299DEST_PATH_IMAGE064
，R4Is composed of
Figure 528947DEST_PATH_IMAGE006
、
Figure 172418DEST_PATH_IMAGE007
、
Figure 38743DEST_PATH_IMAGE008
、
Figure 157877DEST_PATH_IMAGE009
、
Figure 767850DEST_PATH_IMAGE010
、
Figure 531407DEST_PATH_IMAGE011
、
Figure 303054DEST_PATH_IMAGE012
、
Figure 660217DEST_PATH_IMAGE013
、
Figure 73881DEST_PATH_IMAGE014
、
Figure 691944DEST_PATH_IMAGE015
、
Figure 759126DEST_PATH_IMAGE016
、
Figure 462640DEST_PATH_IMAGE017
、
Figure 414415DEST_PATH_IMAGE018
Or
Figure 886985DEST_PATH_IMAGE019
；R12Selected from H, halogen, -OH, -NH2Or (C)1-C3) An alkyl group.
In some embodiments, a compound having the structure of formula I-b, a tautomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, R12Selected from H, halogen, -OH, -NH2Or a methyl group; in some embodiments, R12Is selected from H.
In some embodiments, the present invention provides the following compounds, tautomers thereof, solvates thereof, or pharmaceutically acceptable salts thereof, but is not limited to the following compound ranges:
Figure 141380DEST_PATH_IMAGE065
Figure 597769DEST_PATH_IMAGE066
Figure 87656DEST_PATH_IMAGE067
Figure 807875DEST_PATH_IMAGE068
Figure 357805DEST_PATH_IMAGE069
。
the invention also provides a preparation method of the compound shown in the formula I:
Figure 770332DEST_PATH_IMAGE070
wherein R is1、R2、R3、R4As defined above.
The invention also provides a pharmaceutical composition, which is prepared by taking the compound or the pharmaceutically acceptable salt thereof as an active ingredient or a main active ingredient and assisting with a pharmaceutically acceptable carrier.
The invention also provides application of the compound in preparation of a medicament for treating and/or preventing diseases.
In some embodiments, the invention provides the use of a compound of the invention in the manufacture of a medicament for the treatment and/or prevention of chloasma, scarring, androgenetic alopecia, seborrheic alopecia, acne, psoriasis, eczema or atopic dermatitis.
The compounds or compositions of the invention may be prepared in any pharmaceutically acceptable dosage form, for example, in a formulation suitable for any mode of administration, oral, parenteral, intraperitoneal, intravenous, intraarterial, transdermal, sublingual, intramuscular, rectal, transbuccal, intranasal, inhalation, vaginal, intraocular, topical, subcutaneous, intraadipose, intraarticular, intraperitoneal or intrathecal.
In a preferred embodiment, the dosage form of the present invention is a paste, a liniment, a lotion, a spray, a tablet, a granule, an oral liquid, a capsule, a drop pill, an enema, a film or an injection.
The definition in the specification is as follows:
“C5～C6monohydric alcohol "means a saturated aliphatic hydrocarbon group containing 5 or 6 carbon atoms substituted with one hydroxyl group, including straight and branched chain groups.
"heterocycle" means a saturated cyclic group of 4 to 7 ring atoms in which one or two or three ring atoms are heteroatoms selected from N, O or S (O) m (where m is an integer from 0 to 2), the remaining ring atoms being C, wherein one or two C atoms may optionally be replaced by a carbonyl group. The rings of the heterocyclyl may be optionally independently substituted with one, two or three substituents.
"alkyl" means a saturated aliphatic group of 1 to 20 carbon atoms, including straight and branched chain groups (a numerical range referred to herein, e.g., "1 to 4", means that the group, in this case alkyl, may contain 1,2,3 or 4 carbon atoms.
"cycloalkyl" means a monocyclic or fused ring all carbon (by "fused" ring is meant that each ring in the system shares an adjacent pair of carbon atoms with other rings in the system) group in which one or more rings do not have a fully linked pi-electron system, examples of cycloalkyl include, without limitation, cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, adamantane, cyclohexadiene, cycloheptane, and cycloheptatriene.
"alkoxy" means-O- (unsubstituted alkyl) or-O- (unsubstituted cycloalkyl). Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like.
"alkylamino" denotes-NH- (unsubstituted alkyl), -NH- (unsubstituted cycloalkyl), -N- (unsubstituted alkyl)2or-N- (unsubstituted cycloalkyl)2. Representative examples include, but are not limited to, methylamino, ethylamino, propylamino, butylamino, cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino and the like.
“（C1-C4) Alkoxycarbonyl oxy (C)1-C4) Alkyl "represents (C)1-C4) alkyl-O-C (O) -O- (C)1-C4) An alkyl group-.
“（C1-C4) Alkylcarbonyloxy (C)1-C4) Alkyl' -represents (C)1-C4) Alkyl C (O) -O- (C)1-C4) An alkyl group-. The compound CLY series or pharmaceutically acceptable salt thereof can be applied to the field of pharmacy, and animal model experiments show that the compound CLY series can obviously reduce the tyrosinase level in the skin and blood of a chloasma mouse model, reduce the expression of liver cell factor (SCF) and C-kit protein in the skin and inhibit the pigmentation of chloasma; the healing of the skin wound surface can be obviously promoted, and the scar formation is reduced; the growth of the hair of an androgenetic alopecia mouse model can be obviously promoted, and the damage of the androgen to hair follicles is reduced; the CLY series can obviously inhibit inflammatory reaction of psoriasis and eczema mouse model. Due to the common pathogenesis of many diseases, the efficacy of the compounds includes, but is not limited to, the above diseases. The compound can be used alone or in combination with other medicines, and provides a new medicine choice for treating the diseases.
Drawings
Figure 1 the CLY series of compounds can obviously reduce psoriasis-like inflammatory reaction of mice.
FIG. 2 CLY-2 Nuclear magnetic assay results.
Detailed Description
The present invention will be further described with reference to the following examples, which are intended to illustrate the present invention and not to limit the scope of the present invention, and all simple modifications of the preparation method of the present invention based on the idea of the present invention are within the scope of the present invention. The following examples are experimental methods without specifying specific conditions, and generally follow the methods known in the art. The test materials used in the following examples were purchased from a conventional biochemical reagent store unless otherwise specified.
Example 1: a process for producing (R) -4- (3H- [1,2,3] triazolo [4,5-b ] pyridin-3-yl) -N- (3-chloropyridin-2-yl) -N- (1-methylpiperidin-3-yl) benzamide (abbreviated as CLY-1) and (R) -4- (3H- [1,2,3] triazolo [4,5-b ] pyridin-3-yl) -N- (3-chloropyridin-2-yl) -N- (1-ethylpiperidin-3-yl) benzamide (abbreviated as CLY-2):
1. composite line
Figure 204855DEST_PATH_IMAGE071
2. The specific implementation mode is as follows:
(1) synthesis of tert-butyl (R) -3- ((3-chloropyridin-2-yl) amino) piperidine-1-carboxylate
Adding (R) -1-tert-butyloxycarbonyl-3-aminopiperidine, 2-bromo-3-chloropyridine, sodium tert-butoxide and dioxane into a 250ml container, stirring under the protection of nitrogen, adding RuPhosPd G3 and ligand RuPhos, heating to 100 ℃, reacting for 7 hours, stopping the reaction, pouring into water, extracting with ethyl acetate for several times, combining ethyl acetate layers, washing with water for 3 times, recovering the ethyl acetate layer to obtain a residual paste, mixing the paste with silica gel, and performing silica gel column chromatography to obtain (R) -3- ((3-chloropyridin-2-yl) amino) piperidine-1-tert-butyl formate.
(2) Synthesis of piperidine amides
Adding 4- (3H- [1,2,3] triazole [4,5-b ] pyridine-3-yl) benzoic acid into a container bottle, adding pre-dried toluene, N, N-dimethylformamide and thionyl chloride, heating and stirring at 30 ℃ until the mixture is clear, and recovering the solvent under reduced pressure to obtain a residual solid. Adding 50ml of (R) -3- ((3-chloropyridin-2-yl) amino) piperidine-1-carboxylic acid tert-butyl ester of predried tetrahydrofuran, stirring to be clear, placing in an ice water bath, adding lithium bistrimethylsilyl amino, stirring for 1 hour, removing the ice water bath, stirring for 2 hours, pouring into water, extracting with ethyl acetate, washing an ethyl acetate layer, and recovering the solvent under reduced pressure to obtain a paste.
(3) Synthesis of piperidinamines
Piperidine amide, dichloromethane, trifluoroacetic acid, stirred at room temperature overnight. Pouring into water, adding sodium bicarbonate to adjust the pH to be = 10-11, extracting with dichloromethane, washing, decompressing and recovering the solvent to obtain pasty residue, and performing silica gel column chromatography to obtain the piperidinamine.
(4) Synthesis of CLY-1
Dissolving piperidine amine in dichloromethane, adding methyl iodide, stirring silver carbonate at room temperature in the dark for 48 hours, and directly performing silica gel column chromatography on the reaction liquid to obtain CLY-1.
Nuclear magnetic resonance data for CLY-1 Chemical Formula: C23H22ClN7O
Hydrogen spectrum d 4-MeOH: 8.83 (1H), 8.60 (1H), 8.54 (1H), 8.29 (2H), 7.82(1H), 7.61(3H), 7.42 (1H), 5.06(1H), 3.82(1H), 3.63(1H), 3.39 (1H), 2.95 (1H), 2.40-1.87 (6H), 1.55-1.41 (1H).
(5) Synthesis of CLY-2
Dissolving piperidine amine in dichloromethane, adding iodoethane and silver carbonate, stirring at room temperature in the dark for 48 hours, and directly performing silica gel column chromatography on the reaction liquid to obtain CLY-2. The CLY-2 mass spectrum is shown in FIG. 2.
The following compounds of table 1 can also be synthesized by the same method:
TABLE 1
Figure 652017DEST_PATH_IMAGE072
Figure 372848DEST_PATH_IMAGE073
。
Example 2: synthesis of (R) -N- (3-chloropyridin-2-yl) -N- (pyrrolidin-3-yl) -3- (1H-tetrazol-5-yl) benzamide (CLY-8 for short)
Figure 538251DEST_PATH_IMAGE074
In step 1, tert-butyl (R) -3- (N- (3-chloropyridin-2-yl) -3-cyanobenzoylamino) pyrrolidine-1-carboxylate was obtained in the same manner as in example 3.
Figure 494574DEST_PATH_IMAGE075
Step 2, adding 4.2 g of (R) -3- (N- (3-chloropyridin-2-yl) -3-cyanobenzoylamino) pyrrolidine-1-carboxylic acid tert-butyl ester, 1g of sodium azide and 2 g of triethylamine hydrochloride into 50ml of N, N-dimethylformamide, stirring at 100 ℃ for reaction for 20 hours, cooling, pouring into 200ml of water, dropwise adding concentrated hydrochloric acid to the pH value of 2-3, filtering to obtain a solid, washing with water, and drying. After dissolving in 50ml of methylene chloride and ml of methanol, 10ml of a dioxane solution of hydrogen chloride at a concentration of 4mol/L was added thereto and the mixture was stirred overnight at room temperature, and the mixture was concentrated under reduced pressure to give a solid which was precipitated on silica gel to give 2.7 g of (R) -N- (3-chloropyridin-2-yl) -N- (pyrrolidin-3-yl) -3- (1H-tetrazol-5-yl) benzamide, MS (ES +): 370 (M + H).
Chemical Formula: C17H16ClN7O
Molecular Weight: 369.81
Hydrogen spectrum CDCl3The data in (1): 0.77 (1H), 2.29 (2H), 2.59 (2H), 3.29 (2H), 4.53 (1H), 6.92 (1H), 7.24 (1H), 7.43 (1H), 7.63 (1H), 7.83 (1H), 8.21 (1H), 8.64 (1H), 8.72 (1H).
The following compounds of table 2 can also be synthesized by the same method:
TABLE 2
Figure 796242DEST_PATH_IMAGE076
Figure 687975DEST_PATH_IMAGE077
Figure 216039DEST_PATH_IMAGE078
Figure 851420DEST_PATH_IMAGE079
Figure 273174DEST_PATH_IMAGE080
Figure 335808DEST_PATH_IMAGE081
。
Example 3: synthesis of (R) -4- (3H- [1,2,3] triazolo [4,5-b ] pyridin-3-yl) -N- (3-chloropyridin-2-yl) -N- (tetrahydro-2H-pyran-3-yl) benzamide (CLY-19 for short).
Step 1: synthesis of (R) -3-chloro-N- (tetrahydro-2H-pyran-3-yl) pyridin-2-amine.
Figure 334857DEST_PATH_IMAGE082
10.1 g of (R) -tetrahydro-2H-pyran-3-amine, 14.0 g of 2-bromo-3-chloropyridine, 12.0 g of sodium tert-butoxide and 100ml of tetrahydrofuran are added into a 250ml three-necked flask, nitrogen is used for protection, stirring is started, 0.1g of palladium acetate, 1' -bi-2-naphthol and tri (dimethylamino) phosphine are added, the temperature is increased to 65 ℃, the reaction is stopped after 12 hours of reaction, the mixture is poured into 500ml of water, 1000ml of ethyl acetate is used for fractional extraction, after ethyl acetate layers are combined, 200 x 3 is used for washing, after ethyl acetate layers are recovered, a residual paste is obtained, samples are stirred by silica gel, and about 8 g of (R) -3-chloro-N- (tetrahydro-2H-pyran-3-yl) pyridine-2-amine is obtained by silica gel column chromatography.
Step 2:
Figure 773929DEST_PATH_IMAGE083
adding 5g of 4- (3H- [1,2,3] triazole [4,5-b ] pyridine-3-yl) benzoic acid into 50ml of dichloromethane, adding 2.5ml of oxalyl chloride and 0.2ml of N, N-dimethylformamide serving as a catalyst, reacting at room temperature until the mixture is clear, recovering the solvent under reduced pressure, adding 50ml of tetrahydrofuran into the residue, adding a tetrahydrofuran solution of 4 g of (R) -3-chloro-N- (tetrahydro-2H-pyran-3-yl) pyridine-2-amine serving as a product in the previous step, cooling to below 5 ℃ in an ice water bath, adding 20ml of a lithium bis (trimethylsilyl) amide 1M solution, stirring at room temperature for reaction overnight, pouring into water, extracting 100ml of x 3 with ethyl acetate, washing with water, recovering ethyl acetate under reduced pressure to obtain the residue, performing column chromatography, this gave about 6 g of (R) -4- (3H- [1,2,3] triazolo [4,5-b ] pyridin-3-yl) -N- (3-chloropyridin-2-yl) -N- (tetrahydro-2H-pyran-3-yl) benzamide, MS (ES +): 435 (M + H).
Can also be synthesized by the same method
Figure 50189DEST_PATH_IMAGE084
（CLY-20）。
Example 4: synthesis of ethyl 1- (5- (4- (4- ((3-chloropyridin-2-yl) ((R) -pyrrolidin-3-yl) carbamoyl) phenyl) -1-methyl-1H-pyrazol-5-yl) -2H-tetrazol-2-yl) isobutyrate (abbreviated as CLY-21).
Step 1:
Figure 159091DEST_PATH_IMAGE085
(1) synthesis of tert-butyl (R) -3- (((3-chloropyridin-2-yl) amino) pyrrolidine-1-carboxylate.
11.8 g of (R) -1-tert-butoxycarbonyl-3-aminopyrrolidine, 11.0 g of 2-bromo-3-chloropyridine, 10.0 g of sodium tert-butoxide and 70ml of toluene are added into a 250ml three-necked flask, nitrogen is used for protection, stirring is started, 0.1g of palladium acetate, 1' -bi-2-naphthol and tri (dimethylamino) phosphine are added, the mixture is heated to 100 ℃ and reacted for 7 hours, the reaction is stopped, the mixture is poured into 500ml of water and extracted with 1000ml of ethyl acetate in portions, ethyl acetate layers are combined and washed with 200 x 3, the ethyl acetate layer is recovered to obtain a residual paste, samples are mixed with silica gel, and about 7 g of (R) -3- ((3-chloropyridin-2-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester is obtained by silica gel column chromatography.
Step 2:
Figure 520802DEST_PATH_IMAGE086
to 5g of (R) -3- (((3-chloropyridin-2-yl) amino) pyrrolidine-1-carboxylic acid tert-butyl ester and 4 g of 4-bromobenzoyl chloride in 100ml of tetrahydrofuran solution was added dropwise 20ml of a 1M lithium bis (trimethylsilyl) amide solution at 0 ℃ overnight with stirring at room temperature, and after dilution with 300ml of ethyl acetate, the mixture was washed with 200ml of water 3 and the ethyl acetate layer was concentrated under reduced pressure to give a residue, which was subjected to column chromatography to give about 4 g of (R) -3- (4-bromo-N- (3-chloropyridin-2-yl) benzoylamino) pyrrolidine-1-carboxylic acid tert-butyl ester.
And step 3: preparation of (R) -3- (N- (3-chloropyridin-2-yl) -4- (4, 4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzamide) pyrrolidine-1-carboxylic acid tert-butyl ester
Figure 497985DEST_PATH_IMAGE087
3 g of tert-butyl (R) -3- (4-bromo-N- (3-chloropyridin-2-yl) benzamido) pyrrolidine-1-carboxylate, 3 g of bis (pinacolato) diboron and 2 g of potassium acetate were added to 30ml of 1, 4-dioxane and stirred, and 0.6 g of palladium chloride was added under nitrogen protection, and the mixture was heated to 100 ℃ and stirred for 5 hours, followed by concentration under reduced pressure and chromatography of the residue on a silica gel column to give 3.1 g of tert-butyl (R) -3- (N- (3-chloropyridin-2-yl) -4- (4, 4,5, 5-tetramethyl-1, 3, 2-dioxaborane-2-yl) benzamide) pyrrolidine-1-carboxylate.
And 4, step 4: synthesis of ethyl 1- (5- (4- (4- ((3-chloropyridin-2-yl) ((R) -pyrrolidin-3-yl) carbamoyl) phenyl) -1-methyl-1H-pyrazol-5-yl) -2H-tetrazol-2-yl) isobutyrate
Figure 894331DEST_PATH_IMAGE088
3 g of tert-butyl (R) -3- (N- (3-chloropyridin-2-yl) -4- (4, 4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) benzamide) pyrrolidine-1-carboxylate, 2.5 g of ethyl 1- (5- (4-iodo-1-methyl-1H-pyrazol-5-yl) -2H-tetrazol-2-yl) isobutyrate, 5g of tripotassium phosphate, 0.1g of methanesulfonic acid (2-dicyclohexylphosphino-2 ',6' -dimethoxy-1, 1' -biphenyl) (2' -amino-1, 1' -biphenyl-2-yl) palladium (II) were added to 50%1, 4-dioxane aqueous solution, under the protection of nitrogen, at 100 ℃ for 5 hours. The reaction mixture was cooled to room temperature, diluted with 200ml of ethyl acetate, and the ethyl acetate layer was separated, washed with 100ml of water x 3, dried over anhydrous sodium sulfate, and ethyl acetate was recovered under reduced pressure to give a residue. The residue was dissolved in 30ml of methylene chloride, 4ml of 4 mol/L1, 4-dioxane hydrogen chloride solution was added, the mixture was stirred for 2 hours, the solvent was recovered under reduced pressure to dryness, and the mixture was separated by silica gel chromatography to obtain about 0.5g of ethyl 1- (5- (4- (4- ((3-chloropyridin-2-yl) ((R) -pyrrolidin-3-yl) carbamoyl) phenyl) -1-methyl-1H-pyrazol-5-yl) -2H-tetrazol-2-yl) isobutyrate. MS (ES +): 565 (M + H).
Can also be synthesized by the same method
Figure 688981DEST_PATH_IMAGE089
（CLY-22）。
Example 5: study of pharmacokinetic Properties of rat
1. The experimental method comprises the following steps:
male SD rats were purchased and randomly assigned, and 12 rats for each of the above compound trials were randomly divided into two groups, wherein 6 rats were administered by intravenous injection (1 mg/kg), blood was collected and plasma was isolated at 0.0833, 0.25, 0.5, 1,2, 4, 6, 8 and 24h after administration, and another 6 rats were administered by gavage (5 mg/kg), and blood was collected and plasma was isolated at 0.25, 0.5, 1,2, 4, 6, 8 and 24h after administration. The concentration of each compound in plasma was determined by LC/MS method and the pharmacokinetic properties of each compound were evaluated by calculating the relevant pharmacokinetic parameters using the phonix WinNonlin 6.2.1 software, calculating its bioavailability in male SD rats.
Results of the experiment
Of all the above compounds, the compounds CLY-1, CLY-2, CLY-3, CLY-4, CLY-5, CLY-8, CLY-11, CLY-12, CLY-15, CLY-16, CLY-17, CLY-18 and CLY-20 have better bioavailability in male SD rats, 69.8%, 72.6%, 69.5%, 59.5%, 53.8%, 68.3%, 52.5%, 46.9%, 49.6%, 66.3%, 48.5%, 42.6% and 46.2%, respectively, indicating that the compounds CLY-1, CLY-2, CLY-3, CLY-4, CLY-5, CLY-8, CLY-11, CLY-12, CLY-15, CLY-16, CLY-17, CLY-18 and CLY-20 have good pharmacokinetic properties, wherein CLY-1, CLY-2, CLY-1, CLY-12, CLY-15, CLY-16, CLY-17 and CLY-20 have good pharmacokinetic properties, CLY-3, CLY-8 and CLY-16 have the best pharmacokinetic properties, so that in some examples, CLY-1, CLY-2, CLY-3, CLY-4, CLY-8 and CLY-16 are selected as representatives for researching the pharmaceutical application of the CLY series of compounds.
Example 6: effect of Compound CLY on model of guinea pig chloasma
1. Experimental methods
1.1 Experimental materials
1.1.1 reagents: progesterone (20 mg/ml) was purchased from Shanghai general pharmaceutical Co., Ltd, arbutin ointment was purchased from Shanghai New Pioneer pharmaceutical Co., Ltd, and tyrosine, Malondialdehyde (MDA), and superoxide dismutase (SOD) kit was purchased from Nanjing, to establish the bioengineering institute.
1.1.2 Instrument: model DY 89-II electric glass homogenizer was purchased from Ningbo New Lang Biotech, Inc., and System biomicroscope (Image-Pro Plus 6.0) was purchased from Media Cybernetics, USA.
1.1.3 Experimental animals: SPF grade healthy inbred female guinea pigs weighing 230 + -30 g were obtained from Shanghai Spiker laboratory animal technology, Inc.
1.1.4 preparation method of the treatment cream: the excipient matrix comprises 15 percent of methyl silicone oil, 6 percent of stearic acid, 5 percent of white vaseline, 5 percent of liquid paraffin, 5 percent of octadecanol, 20 percent of glycerol, 1 percent of alkylaryl polyglycol ether, 1 percent of fatty alcohol-polyoxyethylene ether, 1 percent of tween-807, 0.1 percent of ethylparaben and 31 to 55 percent of distilled water which are respectively mixed with a proper amount of CLY series compounds to form 0.25 percent of mixed emulsion. As used in this example, the cream base refers to the base component of the cream from which the active ingredient is removed.
1.2 animal grouping and modeling
According to the weight number, the test pieces are divided into a model control group (smearing cream matrix), a blank control group (smearing cream matrix), a CLY-1 treatment group (smearing 0.25% of CLY-1 cream on the skin), a CLY-2 treatment group (smearing 0.25% of CLY-2 cream on the skin), a CLY-3 treatment group (smearing 0.25% of CLY-3 cream on the skin), a CLY-4 treatment group (smearing 0.25% of CLY-4 cream on the skin), a CLY-8 treatment group (smearing 0.25% of CLY-8 cream on the skin), a CLY-16 treatment group (smearing 0.25% of CLY-8 cream on the skin), a positive treatment group (smearing 0.25% of arbutin cream on the skin) and 6 pieces of each group by adopting a random arrangement table method. Except for the blank control group, 20mg/ml progesterone injection (7.5 mg/kg) is injected into the root of the hind leg intramuscularly in each group of guinea pigs, and the chloasma model is established by continuous injection for 30d 1 time per day. The guinea pig back model area skin is uniform, stable and clear in boundary dark brown colored spot, which is successful in model replication. After modeling, the backs of the guinea pigs in the model control group, the blank control group, the CLY-1 treatment group, the CLY-2 treatment group, the CLY-3 treatment group, the CLY-4 treatment group, the CLY-8 treatment group, the CLY-16 treatment group and the positive treatment group are coated with corresponding emulsifiable paste for intervention, 1 time per day and 30 days continuously.
1.3 Observation index
(1) Determination of tyrosine, MDA content, SOD activity
Washing 1 piece of skin tissue of all guinea pigs with pre-cooled normal saline, removing subcutaneous fat and other connective tissues, wiping to dry, cutting each piece of skin tissue to 0.5g, placing into 5 small test tubes containing 2.0 ml of pre-cooled normal saline, homogenizing at 10 r/min with high speed disperser for 10s, repeating for 1 time, centrifuging at 3500 r/m for 15 min, and collecting supernatant. Tyrosine is measured by a high performance liquid phase method, MDA is measured by a thiobarbituric acid method, SOD is measured by a xanthine oxidase method, and the tyrosine, the MDA content and the SOD activity are detected according to a kit specification.
(2) Pathomorphological observations of skin melanocytes
All guinea pigs were prepared with 1 skin tissue block, approximately 2cm x 1 cm, fixed with 10% paraformaldehyde, examined for pathological tissue, immunohistochemically stained, observed for melanocyte staining and number, and judged positive cells according to literature: none, 0 min; <15%, 0.5 min; <30%, 1 min; >30%, 2 min. And (3) observing 5 visual fields of each section, quantitatively analyzing by using a BX50F4 North navigation pathological image analysis system after finding positive targets showing brown reaction in cytoplasm of epidermal skin and epithelial cells of annexes of each guinea pig, and obtaining the average area, the ratio of the target to the area of a statistical field (area density), the ratio of the number of the targets to the area of the statistical field (number density), the average gray scale, the average optical density and the integral optical density of the melanin positive targets of the 5 visual fields of each guinea pig.
1.4 statistical methods
Statistics with SPSS16.0 softwareThe measured data are averaged + -standard deviation: (xS), between groups using one-way anova, between groups using t-test, P<A difference of 0.05 is statistically significant.
Results of the experiment
(1) Tyrosine, MDA content and SOD activity of each group of guinea pigs
The results of the tests of the guinea pigs for tyrosine, MDA content and SOD activity are shown in Table 3. The skin tyrosine and MDA contents of the guinea pigs in the model group are higher than those in the blank group, and the SOD activity is lower than that in the blank group, which indicates that the establishment of the skin chloasma model is successful; compared with the model group, the skin of the CLY-1 treatment group, the CLY-2 treatment group, the CLY-3 treatment group, the CLY-4 treatment group, the CLY-8 treatment group, the CLY-16 treatment group and the positive treatment group has lower tyrosine and MDA content, and the SOD activity is increased, and the difference has statistical significance (P is less than 0.05).
TABLE 3 comparison of tyrosine, MDA content and SOD activity in guinea pigs of each group
Figure 272409DEST_PATH_IMAGE090
P <0.05 compared to model group.
(2) The area, number and depth of melanocytes of guinea pigs in each group
The area, number and depth of melanocytes of guinea pigs in each group are shown in tables 4 and 5. Compared with the blank group, the skin melanin deposition area of the guinea pig in the model group is increased, the number of melanin cells is increased, the optical density is increased, and the pigmentation is deepened; compared with the model group, the areas of melanin pigmentation of the skin of the guinea pigs in the PCSK9 inhibitor treatment group and the positive treatment group are reduced, the number of melanin cells is reduced, the optical density is reduced, and the pigmentation is lightened, and the PCSK9 small-molecule compound inhibitor group is the most obvious.
TABLE 4 comparison of the area and quantity of melanocytes of guinea pigs in each group
Figure 53283DEST_PATH_IMAGE091
P <0.05 compared to model group.
TABLE 5 comparison of melanocyte depth of groups of guinea pigs
Figure 179502DEST_PATH_IMAGE092
P <0.05 compared to model group.
Conclusion of the experiment
CLY-1, CLY-2, CLY-3, CLY-4, CLY-8 and CLY-16 can be used for treating chloasma by increasing SOD enzyme activity in skin tissue, reducing tyrosine and MDA contents, inhibiting tyrosinase activity of melanocyte and melanoma cell, enhancing oxidation-reduction reaction of skin cell, reducing free radical production, and inhibiting melanin formation.
EXAMPLE 7 Effect of Compound CLY on rat scar model
1. Experimental methods
1.1 preparation method of the treatment cream: the excipient matrix comprises 15 percent of methyl silicone oil, 6 percent of stearic acid, 5 percent of white vaseline, 5 percent of liquid paraffin, 5 percent of octadecanol, 20 percent of glycerol, 1 percent of alkylaryl polyglycol ether, 1 percent of fatty alcohol-polyoxyethylene ether, 1 percent of tween-807, 0.1 percent of ethylparaben and 31 to 55 percent of distilled water which are respectively mixed with a proper amount of CLY series compounds to form a mixed emulsion. The emulsion base used in this example refers to a base component of the emulsion from which the active ingredient is removed.
1.2 grouping and modeling of experimental animals: male SPF grade rats, weighing 210 ± 28 g, were from southern medical center. Rats were numbered according to body weight, and model control group (applying cream base), CLY-1 treatment group (applying 0.5% CLY-1 cream to the skin), CLY-2 treatment group (applying 0.5% CLY-2 cream to the skin), CLY-3 treatment group (applying 0.5% CLY-3 cream to the skin), CLY-4 treatment group (applying 0.5% CLY-4 cream to the skin), CLY-8 treatment group (applying 0.5% CLY-8 cream to the skin), and CLY-16 treatment group (applying 0.5% CLY-16 cream to the skin) were performed by random permutation table method, and each group had 6 animals. Each group of rats was anesthetized with 2% sodium pentobarbital (120 mg/kg) by intraperitoneal injection and then fixed on an operating table, and then a 4X 5cm piece of intact skin was selected on the left side of the back, 8% sodium sulfide was used for depilation, and a 2.4cm diameter circular wound reaching the muscular fascia was cut at the depilation site with tissue scissors, and a part of the muscular surface fascia was destroyed. The animals are raised in cages to prevent rats from biting and licking. The wound surface is coated with 2% iodine tincture for routine disinfection every day, and the wound surface healing condition of rats is observed.
Results of the experiment
2.1 rat wound observation results
The wound surface was routinely sterilized every day, and rat wound surfaces were observed at 1d, 3d, 5d, 7d, 12d, and 20 d. The wound recovery speed of the CLY-1 treatment group, the CLY-2 treatment group, the CLY-3 treatment group, the CLY-8 treatment group and the CLY-16 treatment group is obviously higher than that of the model group from the 5 th day, and the wound area is gradually reduced. On day 12, the wounds of the CLY-1 treatment group, the CLY-2 treatment group, the CLY-3 treatment group, the CLY-4 treatment group, the CLY-8 treatment group and the CLY-16 treatment group had been substantially restored, and the model group had still remained about 0.5cm2The wound surface of the size. By day 20, the wound surface had recovered in each group, the model control group left a distinct scar, while the CLY-1 treatment group, the CLY-2 treatment group, the CLY-3 treatment group, the CLY-4 treatment group, the CLY-8 treatment group and the CLY-16 treatment group left only unequal amounts of pigmentation.
Conclusion of the experiment
CLY-1, CLY-2, CLY-3, CLY-4, CLY-8 and CLY-16 can obviously promote the healing of skin wound and reduce the formation of scars.
EXAMPLE 8 Effect of the CLY series of Compounds on the model of alopecia in rats
1. Experimental methods
1.1 materials
(1) The preparation method of the compounds CLY-1, CLY-2, CLY-3, CLY-4, CLY-8 and CLY-16 tincture comprises the following steps: mixing 75% ethanol with appropriate amount of CLY-1, CLY-2, CLY-3, CLY-4, CLY-8, and CLY-16 respectively, and making into tincture with different concentrations.
(2) Positive therapeutic agents: 5% Minoxidil tincture (trade name: tendy, Zhejiang Marshall pharmaceutical Co., Ltd.)
(3) Experimental animals: SPF grade Wistar rats, male, were from shanghai slaike laboratory animals llc.
1.2 animal grouping and modeling
Wistar rats were randomly divided into a negative control group (externally applied 75% ethanol), a model group (externally applied 75% ethanol), a positive control group (externally applied 5% minoxidil tincture), a CLY-1 externally applied treatment group (externally applied 5% CLY-1 tincture), a CLY-2 externally applied treatment group (externally applied 5% CLY-2 tincture), a CLY-3 externally applied treatment group (externally applied 5% CLY-3 tincture), a CLY-4 externally applied treatment group (externally applied 5% CLY-4 tincture), a CLY-8 externally applied treatment group (externally applied 5% CLY-8 tincture), a CLY-16 externally applied treatment group (externally applied 5% CLY-16 tincture), a CLY-1 intravenous injection group (2 mg/kg. d), a CLY-2 intravenous injection group (2 mg/kg. d), a CLY-3 intravenous injection group (2 mg/kg. d), a CLY-4 intravenous injection group (2 mg/kg. d) CLY-8 intravenous group (2 mg/kg. d), and CLY-16 intravenous group (2 mg/kg. d), each group containing 10 animals. A4 cmx5cm area of the back was selected for each rat before the experiment to remove hairs as an observation area. Except for the negative control group, the rat neck is injected with testosterone propionate injection (5 ml/(kg. d)) subcutaneously for 1 time per day and 60 days continuously to establish an SA model. After 4 weeks of continuous subcutaneous injection of testosterone propionate, the rats gradually lose hair, and the residual hair becomes fine and crisp, thus proving that the alopecia model is successfully established. Meanwhile, the skin is smeared and administrated, the back observation area of the rat of the corresponding drug group is smeared respectively according to 1 mL/(once, twice), 2 times a day, and the administration interval is 8 h. Intravenous administration is once daily. The negative control group and the model control group are smeared with 75% ethanol solution for 1 mL/(only once), 2 times a day and 60 days continuously.
1.3 Observation index and test method
Every 15 days, 10 hairs were plucked from the observation area of the back of each rat, and the length of the hairs was measured with a vernier caliper. After administration for 60 days, the skin of the observation area is taken, and the histopathological changes of the hair follicle and the sebaceous gland of the skin of the rat are observed by conventional tissue dehydration, paraffin embedding, HE staining and optical microscopy. Semi-quantitative analysis was performed on each group of lesions. The classification criteria are as follows: skin dermal tissue cells and subcutaneous hair follicle, sebaceous gland structures are normally scored as "one": the skin dermis has no hyperplasia, the lesion of hair follicle and sebaceous gland is limited, and the hypodermis has no inflammation which is marked as +/-minus or plus: the dermal tissue of the skin has no obvious hyperplasia, the hair follicle has obvious cystic change, the sebaceous gland has no obvious hyperplasia, and the subcutaneous inflammation has no sign "+": the dermal tissue of the skin has segmental hyperplasia, which is not obvious, a small part of hair follicles have cystic degeneration, the sebaceous gland has mild hyperplasia and hypertrophy, and no obvious inflammation is seen in the subcutaneous part and is marked as "+": the dermal tissue cells of the skin have segmental hyperplasia of different degrees, and part of hair follicles become cystic, so that the size of the hair follicles is not uniform, and the peripheral parts have no cells. There was hyperplasia of sebaceous glands, there were fewer nuclei in the body of the hyperplastic glands, and mild inflammatory hyperplasia of subcutaneous tissue in individual rats was marked as "+ + +".
Results of the experiment
2.1 Effect of CLY on Hair growth in rats
The hair length of rats in each treatment group is longer than that of the model control group on the 15 th, 30 th, 45 th and 60 th days after the administration, the difference is statistically significant (P <0.01), and compared with the positive treatment group, the difference is statistically significant (P <0.05), and the results are shown in a table 6.
TABLE 6 Effect of groups on rat Hair growth Length
Figure 754840DEST_PATH_IMAGE093
The differences compared to the model control group were statistically significant (P < 0.01).
2.2 Effect of CLY on the morphology of dermal superficial hair follicles in skin tissue of rat observation area
The skin dermal tissue cells of a part of the rats in the model group have different degrees of segmental thickening, and the subcutaneous tissues of the rats have slight lymphocyte hyperplasia; part of rat subcutaneous hair follicles have obvious cystic change and are different in size, and exfoliative keratin exists in enlarged hair follicle cavities. The skin dermal tissue cells, subcutaneous hair follicles and sebaceous gland lesions of rats in each treatment group are reduced to different degrees compared with the model group. The number of damaged hair follicles of the rat skin of each treatment group is obviously reduced compared with that of the model control group, and the difference has statistical significance (P < 0.01). Compared with the model control group, the pathological changes of the skin tissue cells, the subcutaneous hair follicles and the sebaceous glands of the rats in each treatment group are obviously reduced, and the difference has statistical significance (P < 0.01). Compared with the positive treatment group, the differences have statistical significance (P < 0.05). See table 7.
TABLE 7 Effect of groups on rat skin Hair follicles and sebaceous glands (Only)
Figure 825564DEST_PATH_IMAGE094
Note: is statistically significant (P <0.01) compared to the model control group.
Conclusion of the experiment
CLY-1, CLY-2, CLY-3, CLY-4, CLY-8 and CLY-16 can obviously promote the hair growth of a mouse alopecia model and reduce the damage to subcutaneous hair follicles and sebaceous glands no matter being externally applied or applied systemically.
Example 9 Effect of CLY series on rabbit ear acne model
1. Experimental methods
1.1 materials
(1) The preparation method of the treatment cream comprises the following steps: the excipient matrix comprises 15 percent of methyl silicone oil, 6 percent of stearic acid, 5 percent of white vaseline, 5 percent of liquid paraffin, 5 percent of octadecanol, 20 percent of glycerol, 1 percent of alkylaryl polyglycol ether, 1 percent of fatty alcohol-polyoxyethylene ether, 1 percent of tween-807, 0.1 percent of ethylparaben and 31 to 55 percent of distilled water which are respectively mixed with a proper amount of CLY series compounds to form a mixed emulsion. The emulsion base used in this example refers to a base component of the emulsion from which the active ingredient is removed.
(2) Positive therapeutic agents: 0.1% adapalene gel (trade name: Dafuwen, manufactured by Gaudemei pharmaceutical Co., France)
(3) Experimental animals: 1.8-2.1 kg of common-grade New Zealand rabbits are male and come from Shanghai Si Laike laboratory animal Limited liability company.
1.2 animal grouping and modeling
New Zealand rabbits are numbered according to body weight and divided into a model control group (smearing cream matrix), a blank control group (smearing cream matrix), a positive treatment group (smearing Dafuwen on the skin), a CLY-1 external treatment group (smearing 0.25% of CLY-1 cream on the skin), a CLY-2 external treatment group (smearing 0.25% of CLY-2 cream on the skin), a CLY-3 external treatment group (smearing 0.25% of CLY-3 cream on the skin), a CLY-4 external treatment group (smearing 0.25% of CLY-4 cream on the skin), a CLY-8 external treatment group (smearing 0.25% of CLY-8 cream on the skin), a CLY-16 external treatment group (smearing 0.25% of CLY-16 cream on the skin), a CLY-1 intravenous injection group (1 mg/kg.d), a CLY-2 intravenous injection group (1 mg/kg.d) by adopting a random arrangement table method, CLY-3 intravenous injection group (1 mg/kg. d), CLY-4 intravenous injection group (1 mg/kg. d), CLY-8 intravenous injection group (1 mg/kg. d), and CLY-16 intravenous injection group (1 mg/kg. d), each group containing 10 animals. Taking the inner side of the right ear of the rabbit as an observation area, taking the inner sides of the left ears of all the rabbits as self negative controls, smearing 95% alcohol, uniformly coating 2% coal tar (Alfa Aesar Chinese company, 2% coal tar solution prepared by 95% alcohol) on the inner sides of the right ears of the model group and the treatment group, uniformly coating sterile cotton swabs on the opening of an ear canal on the inner side of the ear of the rabbit within the range of about 2cm multiplied by 2cm for 1 time every day and 0.5 mL each time, wiping the medicine-coated part at the previous time by warm water, and continuously coating for 14 days to establish an acne micro-acne model. The local skin changes including ear thickness, hardness, roughness and the presence or absence of black keratotic plugs at the hair follicle opening were visually observed. The materials are sacrificed and taken after 18h of the last coating, a 5 mm puncher is used for punching holes at the medicine coating part to take skin tissues, 10 percent formaldehyde is used for fixation, the sections are embedded by paraffin, HE staining is carried out, and then pathological histological observation and analysis are carried out.
1.3 Observation index
Histological judgment grading standard of the acne model: grade 3 on histological scale. The 0 grade 'one' is that the funnel part only has loosely keratinized cells and has no acne generation; grade 1 is red skin on the surface of rabbit ears, or a small amount of compact keratinized substance is seen in the infundibulum of hair follicle, and the infundibulum is not expanded '+';grade 2, the medium dense keratinized material is seen in the infundibulum of the hair follicle, and extends to the sebaceous gland, and the infundibulum expands by "2 +", along with hyperplasia of the sebaceous gland duct; grade 3 is that there are extensive keratinized substances in hair follicle, the dense kerato embolism in hair follicle causes the hair follicle to expand heavily, the sebaceous gland duct epithelium grows obviously, the skin bulges, scar, some sebaceous glands take place to regress "3 +".
Observing the pathological change of the tissues under a microscope, measuring the thicknesses of different epidermis at 5 positions on one section by using a Biomias99 image analysis system, and calculating an average value; detecting the areas of 2 hair follicles with the same position and the most complete structure in 4 sections and the diameters of 4 sebaceous glands, calculating the average values of the areas, and subtracting the left and right external auditory canal data of each group of rabbits to obtain the epidermal thickness difference, hair follicle area difference and sebaceous gland diameter difference of the left and right ears of each rabbit.
1.4 statistical treatment
Statistical analysis was performed using SPSS16 software. The self-left and self-right controls adopt a paired t test, and the comparison among the groups adopts the t test, and the difference is that P is less than 0.05, so that the statistical significance is achieved.
Results of the experiment
And (4) visual observation: after the coating with coal tar oil for 14 d, the skins of the left ears of all the groups of rabbits are soft, the hair follicle openings of the external auditory canals of the rabbits are orderly arranged, and no acne, pimple, pustule and the like are seen. The right ear of the rabbit of the model control group is coated with coal tar, the thickness of the back ear is increased, the skin is hard, the surface is rough and dry, most of hair follicle mouths are blackheads, hair follicle mouths are raised to form papules, the contact is hard, and parts of the hair follicle mouths are fused into pieces. The right ear of each external treatment group showed mild, thick, dry and fleshy skin with a small amount of blackheads. Each intravenous injection group shows that most follicular papules of the right ear of the rabbit are removed, the skin becomes thin and soft, the acne is obviously reduced, the pore is obviously reduced, no desquamation exists, and the appearance is basically similar to that of the normal rabbit ear. Compared with the right ear and the left ear of the positive treatment group, the skin of the rabbit is slightly reddened, a little desquamation exists, and a little acne appears.
And (3) observing a tissue section: the left ear of the model group showed a thin epidermis, visible hair follicles, and a clear junction between the dermis and epidermis. After the model group right ear is modeled, the epidermis is thickened, the hyperkeratosis is caused, the granular layer and the acantho layer are thickened, the hair follicle is blocked by an angular plug, the hair follicle is enlarged and extends to the sebaceous gland, and the hair follicle infundibulum is filled with keratinized substances, so that the hair follicle infundibulum is enlarged to be in a pot shape; the dermal superficial capillary vessel expands, the periphery of the hair follicle is scattered and infiltrated by inflammatory cells, and a small amount of neutrophils are contained; the number of sebaceous glands increases and the volume of sebaceous glands increases.
Experimental histological grading of acne under each group of lenses (see table 8): compared with the right ear (experimental control) and the left ear (blank control) of the rabbit in the model group, the difference has statistical significance (P is less than 0.05), which indicates that the rabbit ear acne model is successfully molded; the differences of the right ears of the rabbits in each treatment group and the right ears of the rabbits in the model group have statistical significance (P is less than 0.05), which indicates that the positive control group and each treatment group can improve the acne skin damage.
TABLE 8 histological grading of acne in each group
Figure 144550DEST_PATH_IMAGE095
As shown in table 9, the differences between the epidermal thickness, hair follicle picture and sebaceous gland diameter of the right ear (experimental control) and the left ear (blank control) of the rabbit in the model group are statistically significant (P <0.05), which proves that the rabbit ear acne model is successfully replicated; the epidermal thickness, hair follicle picture and sebaceous gland diameter of the right ear of each treatment group of rabbits are reduced compared with those of the right ear of the model group of rabbits, the difference has statistical significance (P is less than 0.05), and the positive control group and each treatment group can improve the pathological damage of acne skin.
TABLE 9 ear epidermal thickness, hair follicle area and sebaceous gland diameter for each group
Figure 643052DEST_PATH_IMAGE096
P <0.05 compared to the model group right ear.
Conclusion of the experiment
The compounds CLY-1, CLY-2, CLY-3, CLY-4, CLY-8 and CLY-16 can obviously relieve the symptoms of rabbit ear acne models, reduce pore blockage and comedo formation and have obvious treatment effect on acne no matter external use or system treatment.
EXAMPLE 10 Compound CLY inhibits psoriasis-like inflammatory response in mice
1. Materials:
positive drug (glucocorticoid drug): mometasone furoate cream (Allosone), a product of Mr. Shanghai Xianlingbao pharmacy Co., Ltd.
Animals: SPF grade healthy inbred mice (C57 BL/6); 8 weeks old.
The preparation method of the CLY cream comprises the following steps: the matrix comprises methyl silicone oil (15%), stearic acid (6%), white vaseline (5%), liquid paraffin (5%), octadecanol (5%), glycerol (20%), alkylaryl polyglycol ether (1%), fatty alcohol-polyoxyethylene ether (1%), tween-807 (1%), ethyl hydroxybenzoate (0.1%), distilled water (about 31-55%), and a proper amount of CLY series compound solution to form a mixed emulsion.
As used in this example, the cream base is the base component of the CLY cream from which the active ingredient is removed.
The experimental method comprises the following steps:
(1) 36 SPF-grade female C57BL/6 mice, 8 weeks old, were purchased and randomly divided into 5 mice each, a blank control group, a model group, a positive control group (external Arolopine cream), a CLY-1 treatment group (external 0.5% CLY-1 cream), a CLY-2 treatment group (external 0.5% CLY-2 cream), and a CLY-16 treatment group (external 0.5% CLY-16 cream). After 80 mg/kg of pentobarbital sodium is anesthetized by intraperitoneal injection, the back is shaved, the area is about 2cm multiplied by 3cm, and the chicken is raised in a single cage for 1 day.
(2) The blank control group was topically applied with vaseline, and the backs of the model, positive control and CLY treated groups were regularly applied with 5% imiquimod cream 62.5mg daily for 6 days, and photographed daily for PASI scoring.
(3) On day 1 of modeling, the blank control group and model group were topically applied withcream base 2 times a day, and the treatment group was topically applied with 0.5% CLY cream 2 times a day.
The experimental results are as follows:
(1) as shown in fig. 1, after continuously applying 5% imiquimod cream for 6 days, the back application areas of the mice in the model group all showed obvious erythema, scaling and infiltration, while the back application areas of the mice in the CLY treatment group all showed obvious slight erythema, scaling and infiltration compared with the mice in the model group, and the erythema, scaling and infiltration of the treatment group were close to those of the positive drug treatment group. The CLY series compounds can obviously inhibit the inflammatory reaction of psoriasis-like mouse models, and the treatment effect is equivalent to that of glucocorticoid medicaments.
Example 11 CLY inhibits inflammatory response in mouse model of eczema
1. Experimental materials:
ovalbumin (OVA): PBS was prepared at 20 g/L and stored at-20 ℃.
Calcipotriol linimentum (daruss linimentum): danish lio pharmaceutical products, ltd.
Positive drug (glucocorticoid drug): mometasone furoate cream (Allosone), a product of Mr. Shanghai Xianlingbao pharmacy Co., Ltd.
The preparation method of the CLY cream comprises the following steps: the matrix comprises methyl silicone oil (15%), stearic acid (6%), white vaseline (5%), liquid paraffin (5%), octadecanol (5%), glycerol (20%), alkylaryl polyglycol ether (1%), fatty alcohol-polyoxyethylene ether (1%), tween-807 (1%), ethyl hydroxybenzoate (0.1%), distilled water (about 31-55%), and a proper amount of CLY series compound solution to form a mixed emulsion. As used in this example, the cream base is the base component of the CLY cream from which the active ingredient is removed.
Animals: SPF grade healthy inbred mice (C57 BL/6); 8 weeks old.
The experimental method comprises the following steps:
30 SPF-grade female C57BL/6 mice 8 weeks old (0.02 kg) were purchased, and each group was divided into 6 mice randomly into a blank control group (6 mice), a model group (6 mice), a positive drug group (6 mice), a CLY-1 treatment group (topical 0.1% CLY-1 cream), a CLY-2 treatment group (topical 0.1% CLY-2 cream or 0.5% CLY-8 cream), a CLY-3 treatment group (topical 0.1% CLY-3 cream), a CLY-4 treatment group (topical 0.1% CLY-4 cream), a CLY-8 treatment group (topical 0.1% CLY-8 cream), and a CLY-16 treatment group (topical 0.1% CLY-16 cream).
Molding: the ears on both sides of the normal control group mice are smeared with 14.3ul of 75% ethanol, and meanwhile, 14.3ul of 1 nmoI/L calcipotriol liniment is smeared on the ears on both sides of the model group, the positive medicine group and the treatment group every day at regular time, 20 g/L OVA 25ul is smeared after air drying, and the model group, the positive medicine group and the treatment group are smeared for 12d modeling continuously 1 time every day.
And (4) from 4 days after the molding is started, coating a cream substrate on ear skins of mice of a blank control group and a model group, coating the clomazone on the ear skins of the mice of a positive medicine group, respectively coating the treatment cream on the ear skins of the mice of each treatment group, taking pictures everyday 2 times a day, continuously taking 10 days, and grading.
The thickness of the mouse pinna was measured and recorded with an ear thickness gauge before and on day 14, respectively. After the measurement on day 14, the mice were sacrificed by removing their necks, blood was taken, and serum was separated.
The ELISA plate was coated with rabbit anti-mouse Interleukin (IL) -4 antibody, overnight at 4 deg.C, stained and the reaction stopped according to the ELISA kit instructions, and serum IL-4 levels were measured. ELISA kits were purchased from Raybiotech, USA.
The experimental results are as follows:
(1) comparison of ear thickness in mice: before modeling, the difference in ear thickness between groups was not statistically significant (P > 0.05). After molding, the ear thickness of each group of mice is shown in Table 10. The model group is obviously higher than each treatment group, the positive medicine group and the blank control group (P is less than 0.01), and the difference between the positive medicine group and each treatment group has no statistical significance (P is more than 0.05).
TABLE 10 ear thickness of mice in each group after model building
Figure 389291DEST_PATH_IMAGE097
(2) Serum IL-4 concentration: prior to modeling, there was no statistical significance for the differences in serum IL-4 concentrations between groups (P > 0.05). Serum IL-4 levels in peripheral blood of each group of mice after molding are shown in Table 11. The model group is significant to other groups (P is less than 0.01), and the difference between the positive drug group and each treatment group has no statistical significance (P is more than 0.05).
TABLE 11 IL-4 levels in peripheral blood of groups of mice after molding
Figure 212891DEST_PATH_IMAGE098

Claims (22)

1. A compound having the structure of formula I, a tautomer thereof, or a pharmaceutically acceptable salt thereof,
Figure DEST_PATH_IMAGE001
formula I
Wherein:
R1is a substituted or unsubstituted pyridyl; the substituent is H, chlorine or (C)1-C4) An alkyl group;
R2is H, halogen, hydroxy, methoxy, amino or methyl;
when R is3Is composed of
Figure DEST_PATH_IMAGE002
、
Figure DEST_PATH_IMAGE003
、
Figure DEST_PATH_IMAGE004
Or
Figure DEST_PATH_IMAGE005
， R4Is composed of
Figure DEST_PATH_IMAGE006
、
Figure DEST_PATH_IMAGE007
、
Figure DEST_PATH_IMAGE008
、
Figure DEST_PATH_IMAGE009
、
Figure DEST_PATH_IMAGE010
、
Figure DEST_PATH_IMAGE011
、
Figure DEST_PATH_IMAGE012
、
Figure DEST_PATH_IMAGE013
、
Figure DEST_PATH_IMAGE014
、
Figure DEST_PATH_IMAGE015
、
Figure DEST_PATH_IMAGE016
、
Figure DEST_PATH_IMAGE017
、
Figure DEST_PATH_IMAGE018
Or
Figure DEST_PATH_IMAGE019
；
When R is3Is composed of
Figure DEST_PATH_IMAGE020
，R4Is composed of
Figure DEST_PATH_IMAGE021
、
Figure DEST_PATH_IMAGE022
、
Figure DEST_PATH_IMAGE023
、
Figure DEST_PATH_IMAGE024
、
Figure DEST_PATH_IMAGE025
、
Figure DEST_PATH_IMAGE026
、
Figure DEST_PATH_IMAGE027
、
Figure DEST_PATH_IMAGE028
、
Figure DEST_PATH_IMAGE029
Or
Figure DEST_PATH_IMAGE030
；
Wherein:
R6and R8Each independently is H, methyl, halogen or (C)1-C4) Alkyl, and R6And R8Not both are halogen;
R12selected from H, halogen, -OH, -NH2Or (C)1-C3) An alkyl group.
2. A compound having the structure of formula I, its tautomer, or its pharmaceutically acceptable salt according to claim 1, wherein R is2Is H, hydroxy or methyl.
3. A compound having the structure of formula I, its tautomer, or its pharmaceutically acceptable salt according to claim 1, wherein R is1The substituent(s) is H, chlorine or methyl.
4. A compound having the structure of formula I, its tautomer, or its pharmaceutically acceptable salt according to claim 1, wherein R is6Is H or methyl, and R8Is H.
5. A compound having the structure of formula I, its tautomer, or its pharmaceutically acceptable salt according to claim 1, wherein R is12Selected from H, halogen, -OH,-NH2Or a methyl group.
6. A compound having the structure of formula I, its tautomer, or its pharmaceutically acceptable salt according to claim 5, wherein R is12Is selected from H.
7. A compound having the structure of formula I-a, a tautomer thereof, or a pharmaceutically acceptable salt thereof,
Figure DEST_PATH_IMAGE031
formula I-a
Wherein,
when R is3Selected from:
Figure DEST_PATH_IMAGE032
or
Figure DEST_PATH_IMAGE033
，R4Is composed of
Figure 333394DEST_PATH_IMAGE006
、
Figure 525341DEST_PATH_IMAGE007
、
Figure 74134DEST_PATH_IMAGE008
、
Figure 693334DEST_PATH_IMAGE009
Figure 491526DEST_PATH_IMAGE010
、
Figure 424847DEST_PATH_IMAGE011
、
Figure 890464DEST_PATH_IMAGE012
、
Figure 618248DEST_PATH_IMAGE013
、
Figure 169315DEST_PATH_IMAGE014
、
Figure 640748DEST_PATH_IMAGE015
、
Figure 199686DEST_PATH_IMAGE016
、
Figure 426268DEST_PATH_IMAGE017
、
Figure 402314DEST_PATH_IMAGE018
Or
Figure 474175DEST_PATH_IMAGE019
；
When R is3Is composed of
Figure DEST_PATH_IMAGE034
，R4
Figure 383226DEST_PATH_IMAGE021
、
Figure 515130DEST_PATH_IMAGE022
、
Figure 978472DEST_PATH_IMAGE023
、
Figure 854024DEST_PATH_IMAGE024
、
Figure 883160DEST_PATH_IMAGE025
、
Figure 389228DEST_PATH_IMAGE026
、
Figure 136604DEST_PATH_IMAGE027
、
Figure 753530DEST_PATH_IMAGE028
、
Figure 404216DEST_PATH_IMAGE029
Or
Figure 81185DEST_PATH_IMAGE030
；
Wherein R is6And R8Each independently is H, methyl, halogen or (C)1-C4) Alkyl, and R6And R8Not both are halogen;
R12selected from H, halogen, -OH, -NH2Or (C)1-C3) An alkyl group.
8. The compound having the structure of formula I-a, its tautomer, or its pharmaceutically acceptable salt according to claim 7, wherein R is12Selected from H, halogen, -OH, -NH2Or a methyl group.
9. The compound having the structure of formula I-a, its tautomer, or its pharmaceutically acceptable salt according to claim 8, wherein R is12Is selected from H.
10. The compound having the structure of formula I-a, its tautomer, or its pharmaceutically acceptable salt according to claim 7, wherein R is6Is H or methyl, and R8Is H.
11. The compound of claim 10 having the structure of formula I-a, which isA tautomer or a pharmaceutically acceptable salt thereof, wherein R is6Is H, and R8Is H.
12. A compound having the structure of formula I-b, a tautomer thereof, or a pharmaceutically acceptable salt thereof,
Figure DEST_PATH_IMAGE035
formula I-b
Wherein R is3Comprises the following steps:
Figure DEST_PATH_IMAGE036
or
Figure DEST_PATH_IMAGE037
，R4Is composed of
Figure 378175DEST_PATH_IMAGE006
、
Figure 533212DEST_PATH_IMAGE007
、
Figure 536941DEST_PATH_IMAGE008
、
Figure 447128DEST_PATH_IMAGE009
、
Figure 106779DEST_PATH_IMAGE010
、
Figure 127825DEST_PATH_IMAGE011
、
Figure 923742DEST_PATH_IMAGE012
、
Figure 4831DEST_PATH_IMAGE013
、
Figure 151779DEST_PATH_IMAGE014
、
Figure 209471DEST_PATH_IMAGE015
、
Figure 187791DEST_PATH_IMAGE016
、
Figure 111885DEST_PATH_IMAGE017
、
Figure 808446DEST_PATH_IMAGE018
Or
Figure 108977DEST_PATH_IMAGE019
；R12Selected from H, halogen, -OH, -NH2Or (C)1-C3) An alkyl group.
13. The compound having the structure of formula I-b, a tautomer thereof, or a pharmaceutically acceptable salt thereof, of claim 12, wherein R is12Selected from H, halogen, -OH, -NH2Or a methyl group.
14. The compound having the structure of formula I-b, a tautomer thereof, or a pharmaceutically acceptable salt thereof, of claim 13, wherein R is12Is selected from H.
15. A compound selected from the group consisting of:
Figure DEST_PATH_IMAGE038
Figure DEST_PATH_IMAGE039
Figure DEST_PATH_IMAGE040
Figure DEST_PATH_IMAGE041
Figure DEST_PATH_IMAGE043
。
16. a method for preparing a compound shown as a formula I:
Figure DEST_PATH_IMAGE044
；
wherein: r1、R2、R3、R4As defined in claim 1.
17. A pharmaceutical composition comprising the compound of any one of claims 1 to 15, a tautomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient or a major active ingredient, together with a pharmaceutically acceptable carrier.
18. Use of a compound according to any one of claims 1 to 15, a tautomer thereof or a pharmaceutically acceptable salt thereof, or a composition according to claim 17, for the manufacture of a medicament for the treatment and/or prophylaxis of a disease.
19. Use of a compound according to any one of claims 1 to 15, a tautomer thereof or a pharmaceutically acceptable salt thereof, or a composition according to claim 17, for the manufacture of a medicament for the treatment and/or prophylaxis of chloasma, scars, alopecia, acne, psoriasis or eczema.
20. A compound according to any one of claims 1 to 15, a tautomer thereof or a pharmaceutically acceptable salt thereof, or a composition according to claim 17 in any of its pharmaceutically acceptable dosage forms.
21. The dosage form of claim 20, which is a formulation suitable for any mode of administration, oral, parenteral, intraperitoneal, intravenous, intraarterial, topical, transdermal, sublingual, intramuscular, rectal, transbuccal, intranasal, inhalation, vaginal, intraocular, topical, subcutaneous, intralipid, intraarticular, intraperitoneal, or intrathecal.
22. The dosage form of claim 21, wherein the dosage form is a paste, a liniment, a lotion, a spray, a tablet, a granule, an oral liquid, a capsule, a drop pill, an enema, a film or an injection.
CN202110668896.0A2021-06-172021-06-17CLY series compounds, preparation method thereof and application thereof in preparing medicinesActiveCN113248501B (en)

Priority Applications (7)

Application NumberPriority DateFiling DateTitle
CN202110668896.0ACN113248501B (en)2021-06-172021-06-17CLY series compounds, preparation method thereof and application thereof in preparing medicines
EP22824326.7AEP4357345A4 (en)2021-06-172022-06-17 CLY COMPOUND, MANUFACTURING METHOD THEREOF AND USE THEREOF IN THE MANUFACTURE OF MEDICINES
US18/571,578US20240300945A1 (en)2021-06-172022-06-17Cly series compound, preparation method therefor and use thereof in preparation of drugs
KR1020247001632AKR20240022602A (en)2021-06-172022-06-17 CLY series compounds and their manufacturing methods and drug manufacturing uses
JP2024510304AJP2024532854A (en)2021-06-172022-06-17 CLY series compounds, their preparation method and use of the prepared drugs
PCT/CN2022/099496WO2022262854A1 (en)2021-06-172022-06-17Cly series compound, preparation method therefor and use thereof in preparation of drugs
CN202310688735.7ACN116803391A (en)2021-06-172023-06-12 Use of WEZ series compounds in preparing products for preventing or/and treating hair loss

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN202110668896.0ACN113248501B (en)2021-06-172021-06-17CLY series compounds, preparation method thereof and application thereof in preparing medicines

Publications (2)

Publication NumberPublication Date
CN113248501A CN113248501A (en)2021-08-13
CN113248501Btrue CN113248501B (en)2021-10-08

Family

ID=77188283

Family Applications (2)

Application NumberTitlePriority DateFiling Date
CN202110668896.0AActiveCN113248501B (en)2021-06-172021-06-17CLY series compounds, preparation method thereof and application thereof in preparing medicines
CN202310688735.7APendingCN116803391A (en)2021-06-172023-06-12 Use of WEZ series compounds in preparing products for preventing or/and treating hair loss

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
CN202310688735.7APendingCN116803391A (en)2021-06-172023-06-12 Use of WEZ series compounds in preparing products for preventing or/and treating hair loss

Country Status (6)

CountryLink
US (1)US20240300945A1 (en)
EP (1)EP4357345A4 (en)
JP (1)JP2024532854A (en)
KR (1)KR20240022602A (en)
CN (2)CN113248501B (en)
WO (1)WO2022262854A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN113248501B (en)*2021-06-172021-10-08南京韦尔优众医药有限公司CLY series compounds, preparation method thereof and application thereof in preparing medicines
WO2024226875A2 (en)*2023-04-282024-10-31Initial Therapeutics, Inc.Compounds, compositions and methods for attenuation of mammalian translation of c-myc or n-myc proteins of the myc proto-oncogene family of bhlh transcription factors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2006008259A1 (en)*2004-07-162006-01-26Janssen Pharmaceutica N.V.Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitabale for the treatment of neurodegenerative disorders
US7122683B2 (en)*2004-11-232006-10-17Pfizer Inc.Amides useful as monoamine re-uptake inhibitors
DE102010002558A1 (en)*2009-11-202011-06-01Symrise Ag Use of physiological cooling agents and agents containing such agents
JP6020396B2 (en)*2012-09-122016-11-02大正製薬株式会社 Medicaments containing azole derivatives
CN105143203A (en)*2013-04-172015-12-09辉瑞大药厂N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en)*2014-10-082016-04-14Pfizer Inc.Substituted amide compounds
EP3442960A1 (en)*2016-04-122019-02-20Esteve Pharmaceuticals, S.A.Arylamide derivatives having multimodal activity against pain
CN107311996A (en)*2016-04-272017-11-03成都贝斯凯瑞生物科技有限公司A kind of amide compound and its application
WO2018192493A1 (en)*2017-04-212018-10-25深圳信立泰药业股份有限公司Piperidine compound as pcsk9 inhibitor
EP3651769B1 (en)*2017-07-122022-01-05Samson Clinical Pty Ltd.Promoting hair growth and treatment of hair loss or excessive hair shedding
US20200270240A1 (en)*2017-07-212020-08-27Icahn School Of Medicine At Mount SinaiBenzothiazole and pyridothiazole compounds as sumo activators
JP2021517141A (en)*2018-03-092021-07-15ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Combination therapy for cardiovascular disease
MX2021008661A (en)*2019-01-182021-08-19Astrazeneca Ab PCSK9 INHIBITORS AND METHODS OF USE THEREOF.
ES3007652T3 (en)*2019-01-182025-03-20Astrazeneca Ab6'-[[(1s,3s)-3-[[5-(difluoromethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-one as pcsk9 inhibitor and methods of use thereof
CN113387945A (en)*2020-03-112021-09-14陈敏Compound PTM-3, PTM-4, preparation method and application of preparing medicine
CN112094268B (en)*2020-11-092021-02-09南京韦尔优众医药有限公司Compound WEZ series, preparation method thereof and application of compound WEZ series in preparation of medicines
CN113248501B (en)*2021-06-172021-10-08南京韦尔优众医药有限公司CLY series compounds, preparation method thereof and application thereof in preparing medicines

Also Published As

Publication numberPublication date
EP4357345A4 (en)2025-06-18
JP2024532854A (en)2024-09-10
CN116803391A (en)2023-09-26
KR20240022602A (en)2024-02-20
WO2022262854A1 (en)2022-12-22
EP4357345A1 (en)2024-04-24
CN113248501A (en)2021-08-13
US20240300945A1 (en)2024-09-12

Similar Documents

PublicationPublication DateTitle
JP5570992B2 (en) Method and composition for treating skin diseases or skin lesions
JP2022116295A (en)Topical compositions and methods for treating inflammatory skin diseases
US9980887B2 (en)Compositions for use in treatment of hyperpigmentation and methods of use thereof
CN113248501B (en)CLY series compounds, preparation method thereof and application thereof in preparing medicines
US20200206231A1 (en)Topical pharmaceutical composition, method for producing the topical pharmaceutical composition, use of topical pharmaceutical composition and method for topical treatment of psoriasis, atopic dermatitis or chronic eczema
JP5685315B2 (en) Pharmaceutical or cosmetic composition comprising nicotinic acid adenine dinucleotide phosphate or a derivative thereof
CN112979762B (en)Cyclic peptide PIZ and use thereof
RU2698796C2 (en)Icotinib-containing topical skin pharmaceutical compositions and use thereof
KR20150018851A (en)Method for treating skin inflammatory diseases
Gupta et al.Keratosis follicularis spinulosa decalvans showing excellent response to isotretinoin
Wu et al.Mitochondria-targeted curcumin microneedles for psoriasis therapy via autophagy activation and epidermal hyperplasia suppression
US20180338964A1 (en)3-(piperidin-4-yl)-isoxazol-3(oh)-ones for treatment of dermatologic disorders
JP6656890B2 (en) Filaggrin production promoter
JP4480128B2 (en) Drug for inhibiting the production of matrix metalloprotease-9
US20230346773A1 (en)Use of pcsk9 inhibitor in preparation of product for treating multiple diseases
Zeng et al.Enhancing skin delivery of tranexamic acid via esterification: synthesis and evaluation of alkyl ester derivatives
TW201740977A (en)Method for relief of and treatment of pruritus
US7232839B2 (en)Benzoisothiazolone compositions
JP2025518798A (en) Use of Tetrahydronaphthyridine Derivatives for the Preparation of Products That Improve Pigmentation - Patent application
JP2010215522A (en)Skin disease treating or skin disease preventing pharmaceutical composition and skin disease preventing cosmetic
KR101221593B1 (en)A composition for suppressing melanogenesis containing H19 microRNA
CN120346320A (en)Application of ACC inhibitor in preparation of hair growth product

Legal Events

DateCodeTitleDescription
PB01Publication
PB01Publication
SE01Entry into force of request for substantive examination
SE01Entry into force of request for substantive examination
GR01Patent grant
GR01Patent grant
[8]ページ先頭
©2009-2025 Movatter.jp